All articles by Daniel Garrun

  1. Rethinking the role of the placebo – new trials test new ratios

    The use of placebos in trials has a long and venerable history. Since the 18th century, when a ship doctor…
    Read More…

    3 Mar
  2. Better together? Combining therapies to slow down cancer growth

    A first-of-its-kind medical study at The Care Oncology Clinic on Harley Street, London, has started work on evaluating whether the…
    Read More…

    14 Dec
  3. Could ZMapp’s rapid approval set a new precedent?

    In August 2014, as the Ebola epidemic rampaged through West Africa, a handful of sufferers were offered an unprecedented lifeline….
    Read More…

    7 Dec
  4. Triple fixed-doses & improved Insulins take centre stage at EASD 2014

    Triple FDCs tipped to shake up already lucrative SGLT-2s market SGLT-2s represent the newest class of the oral anti-diabetic medications…
    Read More…

    25 Nov
  5. The International Clinical Trials Registry Platform – perils, pitfalls and possibilities

    When it comes to clinical trials, publication bias is a well-acknowledged problem. Statistically speaking, trial sponsors are more likely to…
    Read More…

    3 Nov
  6. The economic case for clinical trials: 10 yr old Progestin study speaks volumes

    Health economics is hardly a field known for its profligacy. These days, large-scale clinical trials are generally viewed as an…
    Read More…

    1 Oct
  7. Sharing clinical trial data responsibly: is enough being done?

    On 1 January 2014, the joint principles on ‘responsible’ sharing of clinical trial data, which were endorsed by the European…
    Read More…

    9 Apr
  8. Pharmaceutical-technology.com launches major industry survey

    Pharmaceutical-technology.com would like to invite you to take part in our latest industry confidence tracking survey, examining industry sentiment around…
    Read More…

    16 Dec
  9. Approving cancer drugs in the UK – where is the line?

    Despite advancements in the treatment of cancer, the devastating effects of the disease remain a global burden. Immense efforts are…
    Read More…

    19 Nov
  10. Time is ticking for trace metals in pharmaceuticals

    While both regulators and drug manufacturers agree on the need to modernise elemental impurity analysis, reaching an agreement has been…
    Read More…

    13 Nov
Close
Close
Close

Go Top